Drugs / 4-Aminosalicylic acid
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00495521 | Jun 2007 → Jul 2008 | Crohn disease | Jacobus Pharmaceutical | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00417690 | Jan → Dec 2007 | ileocolitis | Jacobus Pharmaceutical | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00004810 | Jun 1996 → ? | ulcerative colitis | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00004423 | Dec 1995 → Mar 1998 | Crohn disease | University of Vermont | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4-Aminosalicylic acid | “Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease” NCT00004423 ↗3“Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis” NCT00004810 ↗ |
| Known as | 4-ASA | “Patients are randomized to receive either oral 4-aminosalicylic acid (4-ASA) or placebo twice a day for 12 weeks.” NCT00004423 ↗1“Patients are randomly assigned to oral 4-aminosalicylic acid (4-ASA) or placebo administered daily for 6 weeks.” NCT00004810 ↗ |
| Known as | PASER | “High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease” NCT00417690 ↗ |
| Route | Oral | “oral 4-aminosalicylic acid (4-ASA)” NCT00004423 ↗ |